Viracta Therapeutics Granted US Patent #12012396 For "HDAC Inhibitor Solid State Forms (For The Treatment Of Cancer, Immune Disorders)"
Portfolio Pulse from Benzinga Newsdesk
VIRX has been granted US Patent #12012396 for 'HDAC Inhibitor Solid State Forms' aimed at treating cancer and immune disorders. This patent could enhance VIRX's intellectual property portfolio and potentially lead to new treatments.
June 18, 2024 | 7:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VIRX has been granted a US patent for 'HDAC Inhibitor Solid State Forms' which could strengthen its intellectual property and lead to new treatments for cancer and immune disorders.
The granting of a patent is a significant milestone for a biotech company as it strengthens its intellectual property portfolio. This can lead to new product developments and potential revenue streams, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100